Loading
Operating again at first relapse, in carefully selected women, added about seven months of life.
DESKTOP III, also ENGOT-ov20, trial NCT01166737 sponsored by the AGO group and published in the New England Journal of Medicine in 2021, showed that operating again at first platinum-sensitive relapse of ovarian cancer, in women carefully selected by a positive AGO score, adds about seven months of life. It randomised 407 patients to secondary cytoreductive surgery plus chemotherapy or chemotherapy alone, met its primary overall survival endpoint, and the benefit was concentrated in patients whose tumour was completely resected. OnCo links it to ovarian cancer, minimally invasive surgery and Andreas du Bois; it contradicted the negative surgery arm of GOG-0213, with patient selection the likely explanation, while the Chinese SOC-1 trial showed a progression benefit. Whether the AGO score can be reproduced outside expert centres is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
408 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Surgery + chemotherapy | 206 | 53.7 months | 0.75 (0.59 to 0.96) | - | link |
| Chemotherapy alone | 201 | 46 months |
Shares Andreas du Bois, Ovarian cancer.
Shares AGO Study Group, Ovarian cancer.
Shares AGO Study Group, Ovarian cancer.
Shares AGO Study Group, Ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-sensitive ovarian cancer.